Drug intelligence / Profile preview

PF-04415060

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules

Overview

**PF-04415060** (also known as BAY 74-4113) is a small molecule inhibitor of diacylglycerol O-acyltransferase 1 (DGAT-1), an enzyme involved in the final step of triglyceride synthesis. Originally discovered by Bayer, it was in-licensed by Pfizer in June 2006 and included in a collaboration with Bristol-Myers Squibb for worldwide development in metabolic disorders. The compound showed promise in preclinical testing for reducing triglyceride accumulation, with potential applications in treating obesity and diabetes by modulating lipid metabolism.[3][7][13]

Targets

DGAT1 (Diacylglycerol O-acyltransferase 1)

Beyond the preview

Go deeper on PF-04415060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-04415060.